Publication | Open Access

Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial

VaccinationVaccine SafetyVaccine DevelopmentImmunologyVaccine TestingSecondary AnalysisMedicineVaccine ResearchHomologous Booster DoseCovid-19